SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001628280-22-026763
Filing Date
2022-10-20
Accepted
2022-10-20 16:57:44
Documents
14

Document Format Files

Seq Description Document Type Size
1 424B5 denaliprosupp424b5final.htm 424B5 839329
2 EX-FILING FEES exhibit107-prosupp424b5fin.htm EX-FILING FEES 24745
3 dnlilogoa01a.jpg GRAPHIC 30236
4 etv3a1.jpg GRAPHIC 396696
5 figure10.jpg GRAPHIC 99412
6 figure11.jpg GRAPHIC 172533
7 figure2.jpg GRAPHIC 462097
8 figure3.jpg GRAPHIC 697742
9 figure5.jpg GRAPHIC 117488
10 figure8.jpg GRAPHIC 350025
11 figure9.jpg GRAPHIC 41089
12 image1.jpg GRAPHIC 189873
13 image_2.jpg GRAPHIC 5258
14 picture4.jpg GRAPHIC 1246559
  Complete submission text file 0001628280-22-026763.txt   6008288
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-263107 | Film No.: 221321625
SIC: 2836 Biological Products, (No Diagnostic Substances)